Leukemia & lymphoma/Leukemia and lymphoma · 2008 · 41 citations · 23 references
MedicineMolecular BiologyOncologyImmunopathologyInflammationMolecular OncologyCancer BiomarkersCancer Cell SignalingCancer Molecular PathologyInflammatory SignalingTumor MarkersCytokine-like SignalingHigh-mobility Group Box 1 ProteinHigh-mobility Group Box 1 SignalingLymphoma BiomarkersLymphoma PathogenesisQuantitative Pcr DetectionTherapeutic Target IdentificationTumor-associated Cytokines
HMGB1 is a high mobility group protein that can act either as a DNA binding protein or extracellularly as a cytokine-like danger signal. Extracellular HMGB1, either actively secreted or passively released by necrotic cells, is linked to inflammation and cancer. Herein, the results of a study to quantify the expression of HMGB1 in lymphomas by quantitative real-time RT-PCR are presented. HMGB1 expression was analysed in 18 non-Hodgkin lymphomas and two lymphoma cell lines. 11/18 primary lymphomas expressed HMGB1 mRNA at a level exceeding the average of normal lymph nodes. Immunohistochemistry showed that HMGB1 positivity is confined to the lymphoma cells. No correlation between HMGB1 expression and grading was found. However, a high percentage of lymphomas is overexpressing a danger-signalling protein. This protein can support the growth and angiogenesis of lymphoma cells in a paracrine way when released e.g. due to necrosis. Thus it constitutes an interesting therapeutic target as well.
23
HMG-1 as a Late Mediator of Endotoxin Lethality in Mice
Haichao Wang, Ona Bloom, Minghuang Zhang et al. · Science · 1999 · 3.4K citations
Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases
Akihiko Taguchi, David C. Blood, G. Del Toro et al. · Nature · 2000 · 1.2K citations
Medicine, Cancer Biology, Oncology +14
Bernard Degryse, Tiziana Bonaldi, Paola Scaffidi et al. · The Journal of Cell Biology · 2001 · 449 citations · Full text